Our current findings support soy isoflavones as an alternative therapy, as we did not show estrogenic effects on ET, VMI, FSH, and estradiol, reinforcing previous research demonstrating that soy isoflavone intake is associated with a reduction in the risk of estrogenic-related cancers [20,21]. Here, BRD2 is linked to cancer.